Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 463

1.

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.

Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM.

J Clin Oncol. 1999 Sep;17(9):2745-51.

PMID:
10561349
2.

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K.

J Clin Oncol. 1996 Jul;14(7):2083-90.

PMID:
8683240
3.

Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.

Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH, Vukov AM, Rowland KM, Krook JE, Michalak JC.

J Clin Oncol. 1999 Jun;17(6):1884-90.

PMID:
10561229
4.

Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.

Chiarion Sileni V, Nortilli R, Aversa SM, Paccagnella A, Medici M, Corti L, Favaretto AG, Cetto GL, Monfardini S.

Melanoma Res. 2001 Apr;11(2):189-96.

PMID:
11333130
5.

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.

Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P, Thatcher N.

Br J Cancer. 2000 Mar;82(6):1158-62.

6.

The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.

McClay EF, McClay ME, Monroe L, Baron PL, Cole DJ, O'Brien PH, Metcalf JS, Maize JC.

Br J Cancer. 2000 Jul;83(1):16-21.

7.

Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.

Serrone L, Zeuli M, Sega FM, Cognetti F.

J Exp Clin Cancer Res. 2000 Mar;19(1):21-34.

PMID:
10840932
8.

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.

Margolin KA, Liu PY, Flaherty LE, Sosman JA, Walker MJ, Smith JW 3rd, Fletcher WS, Weiss GR, Unger JM, Sondak VK.

J Clin Oncol. 1998 Feb;16(2):664-9.

PMID:
9469356
9.

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).

Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W.

Br J Cancer. 2001 Apr 20;84(8):1036-42.

10.
12.

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.

Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup.

J Clin Oncol. 2002 Mar 15;20(6):1600-7.

PMID:
11896110
13.

Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).

Sertoli MR, Queirolo P, Bajetta E, Del Vecchio M, Comella G, Barduagni L, Bernengo MG, Vecchio S, Criscuolo D, Bufalino R, Morabito A, Cascinelli N.

Melanoma Res. 1999 Oct;9(5):503-9. Erratum in: Melanoma Res. 2007 Oct;17(5):340. DelVecchio, M [corrected to Del Vecchio, M].

PMID:
10596917
14.

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.

Atzpodien J, Lopez Hänninen E, Kirchner H, Franzke A, Körfer A, Volkenandt M, Duensing S, Schomburg A, Chaitchik S, Poliwoda H.

Eur J Cancer. 1995 Jun;31A(6):876-81.

PMID:
7646914
15.
16.

Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.

Jelić S, Babovic N, Kovcin V, Milicevic N, Milanovic N, Popov I, Radosavljevic D.

Melanoma Res. 2002 Feb;12(1):91-8.

PMID:
11828263
17.

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.

Propper DJ, Braybrooke JP, Levitt NC, O'Byrne K, Christodoulos K, Han C, Talbot DC, Ganesan TS, Harris AL.

Br J Cancer. 2000 Jun;82(11):1759-63.

20.

Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.

Daponte A, Ascierto PA, Gravina A, Melucci MT, Palmieri G, Comella P, Cellerino R, DeLena M, Marini G, Comella G; Italian Cooperative Oncology Group.

Cancer. 2000 Dec 15;89(12):2630-6.

PMID:
11135225
Items per page

Supplemental Content

Write to the Help Desk